Your shopping cart is currently empty

SCH529074 is a selective activator of p53 (Ki = 1 μM) and can be used in studies about non-small-cell lung carcinoma. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | - | In Stock | |
| 2 mg | $38 | - | In Stock | |
| 5 mg | $58 | - | In Stock | |
| 10 mg | $106 | - | In Stock | |
| 25 mg | $232 | - | In Stock | |
| 50 mg | $345 | - | In Stock | |
| 100 mg | $493 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $69 | - | In Stock |
| Description | SCH529074 is a selective activator of p53 (Ki = 1 μM) and can be used in studies about non-small-cell lung carcinoma. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53. |
| Targets&IC50 | p53 DBD:1-2 μM (Ki) |
| In vitro | SCH529074 (2-4 µM) reduces cell viability and decreases to 20-25% in p53 mutant cells including H157, H1975, and H322, and to 68% in the p53 WT cell line A549 at 4 µM. SCH 529074 (2-4 µM) induces NSCLC cells including H157, A549, HCT116, and HCT116 p53-/- arrested at the G0/G1 phase (59%; 72%; 66%; and 57%)[2]. |
| In vivo | In female nude mice, 5–7 weeks of age, received subcutaneous inoculation of DLD-1 human colorectal carcinoma cells, SCH529074 (orally; 30 and 50 mg/kg) reduces 79 and 43% of tumor growth with the plasma exposure of 0.26–0.55 μm at 30 mg/kg and 0.39-0.79 μm at 50 mg/kg[1]. |
| Synonyms | SCH 529074 |
| Molecular Weight | 563.56 |
| Formula | C31H36Cl2N6 |
| Cas No. | 922150-11-6 |
| Smiles | CN(C)CCCNc1nc(CN2CCN(CC2)C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)nc2ccccc12 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 33 mg/mL (58.56 mM), Sonication is recommended. DMF: 33 mg/mL (58.56 mM), Sonication is recommended. DMSO: 22.5 mg/mL (39.92 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (1.77 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO/Ethanol/DMF
Ethanol/DMF
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.